SOUTH SAN FRANCISCO, Calif. — August 8, 2025 — BiotechReporter,news — Assembly Biosciences, Inc. (Nasdaq: ASMB) has announced the pricing of an underwritten, registered offering of 5,591,840 shares of common stock and pre-funded warrants to purchase 1,040,820 shares of common stock, along with Class A and Class B warrants to purchase 6,632,660 shares of common stock. The combined price is $19.60 per share and $19.599 per pre-funded warrant.
Each pre-funded warrant has a nominal exercise price of $0.001 per share and is immediately exercisable. Class A warrants are exercisable at $21.60 per share and expire five years from issuance or 30 days after Assembly Bio completes enrollment for its Phase 2 clinical study evaluating ABI-5366 vs. valacyclovir. Class B warrants, also at $21.60 per share, are exercisable from November 15, 2026, to December 31, 2026, but terminate if Assembly Bio secures $75.0 million in non-dilutive capital through a collaboration agreement before November 15, 2026.
The offering includes participation from Commodore Capital, Blackstone Multi-Asset Investing, Farallon Capital Management, L.L.C., Janus Henderson Investors, RA Capital Management, and other healthcare funds.
Gilead Sciences, Inc. will separately purchase 2,295,920 shares of common stock and warrants in a private placement at the same price. Both the offering and private placement, expected to close on August 11, 2025, are contingent upon each other, with Assembly Bio planning to use the net proceeds for general corporate purposes.
Guggenheim Securities is the lead book-running manager, with Mizuho also acting as a book-running manager. Registration statements are effective with the SEC, and prospectus supplements are available on the SEC’s website.
Shannon Ryan
SVP, Investor Relations, Corporate Affairs and Alliance Management
(415) 738-2992
investor_relations@assemblybio.com
Source: Assembly Biosciences
